Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1039 of 6351
-
Could a blood injection revive aging ovaries?
Disease control Recruiting nowAutologous PRP intra ovarian infusion may improve ovarian response and women's hormonal profile and may promote folliculogenesis in perimenopausal women.
Phase 2/3 • Sponsor: Genesis Athens Clinic • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Can genes predict chemo success in pancreatic cancer?
Disease control Recruiting nowThis is a research study to evaluate how the genetic makeup of Pancreatic Ductal Adenocarcinoma (PDAC) can affect the response to FDA-approved chemotherapy treatment, FOLFIRINOX, given before surgery to remove the tumor. Certain types of PDAC tumors can be surgically resected (re…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Could keytruda before surgery boost colorectal cancer outcomes?
Disease control CompletedThis is a window of opportunity translational study investigating the use of pre-operative pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug aims to unmask melanoma to the immune system
Disease control OngoingCancers attract myeloid-derived suppressor cells (MDSCs) that prevent our own immune responses from destroying the cancer. This study will be the first study to begin to determine if the newly discovered drug SX-682 can block cancers from attracting MDSCs. This first study will e…
Phase 1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Bionic breakthrough: new surgery lets amputees 'Feel' their prosthetic foot
Disease control CompletedThis study involves the functional testing of a new lower extremity prosthesis by healthy, active participants with fully healed transtibial (below knee) amputations. The study design calls for an experimental group of eleven participants who received two agonist-antagonist myone…
Sponsor: Massachusetts Institute of Technology • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New hope for kids with dwarfism: daily shot may boost growth
Disease control OngoingThis is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111…
Phase 2 • Sponsor: BioMarin Pharmaceutical • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a walking routine delay resistance to breast cancer therapy?
Disease control OngoingThis study will test any good and bad effects of aerobic exercise performed while you are receiving the usual first-line treatment for metastatic breast cancer. The researchers think that exercise helps delay the development of resistance to hormone therapy while slowing the grow…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New triple therapy aims to tame melanoma treatment's worst side effects
Disease control OngoingThis is a Phase II, open-label, single arm study. The study will consist of an assessment of the safety and tolerability of tocilizumab administered concurrently at 4 mg/kg every 6 weeks for 5 doses in combination with ipilimumab and nivolumab for four induction doses to week 12,…
Phase 2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Could a lower dose of this breast cancer drug be safer and still work?
Disease control CompletedThe purpose of the study was to evaluate the safety and efficacy of a reduced ribociclib starting dose of 400 mg in combination with a non-steroidal aromatase inhibitor (NSAI) (letrozole or anastrozole) for the treatment of pre- and postmenopausal women with hormone receptor-posi…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy combo shows promise in esophageal cancer trial
Disease control CompletedThis is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of tislelizumab (BGB-A317) versus placebo in combination with chemoradiotherapy in participants with localized esophageal squamous cell carcinoma (ESCC).
Phase 3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New heart valve device shows promise, but trial halted early
Disease control OngoingTo evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR. As of 28-May-2025, Boston Scientific Corporation (BSC) announced the …
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New combo therapy shows promise for tough kidney cancer
Disease control OngoingThis phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other par…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Smarter prostate cancer screening: a blood test that may cut unnecessary biopsies
Diagnosis OngoingThis ambispective observational cohort study will evaluate the clinical performance of the ClarityDX Prostate blood test in men with a prostate-specific antigen (PSA) level of 3 ng/mL or higher who are undergoing prostate biopsy due to suspicion of prostate cancer. The study will…
Sponsor: Nanostics • Aim: Diagnosis
Last updated Jul 26, 2026 00:00 UTC
-
New hope for teens with schizophrenia? drug trial underway
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
Phase 3 • Sponsor: Gedeon Richter Plc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Could skipping radiation be just as effective for rectal cancer?
Disease control Recruiting nowThis study is a non-inferiority phase III randomised trial comparing preoperative chemotherapy alone (modified FOLFIRINOX) to chemotherapy followed by chemoradiotherapy in patients with primary resectable locally advanced rectal cancer. The primary endpoint of the study is 3-year…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
A simple breath test could spot mesothelioma years earlier
Diagnosis Stopped earlyThis is a two phase study, The first phase (phase 1) will identify potential biomarkers among asbestos exposed individuals with pleural mesothelioma. The second phase (phase 2), is a double blinded case-matched controlled study to determine the predictive capability, sensitivity,…
Sponsor: Henry Ford Health System • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Pancreatic cancer trial combines chemo with immune boosters
Disease control CompletedThis study will test the effectiveness (anti-tumor activity), safety, and ability to increase the body's immune system to fight pancreatic cancer by combining standard chemotherapy before and after surgery, with study drug PD-1 antibody, pembrolizumab, with and without study drug…
Phase 2 • Sponsor: Lei Zheng • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New drug combo shows promise for Hard-to-Treat lung cancer
Disease control CompletedThis is an open-label, multicenter, non-randomized, Phase 2 study to determine the safety, tolerability and efficacy of encorafenib given in combination with binimetinib in patients with BRAFV600E-mutant metastatic non-small cell lung cancer (NSCLC). Patients who are either treat…
Phase 2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can big data unlock the secrets of a deadly aortic emergency?
Knowledge-focused Recruiting nowThe Nordic Consortium for Acute Type A Aortic Dissection-2 (NORCAAD-2) is a multicenter research collaboration involving up to 19 units in the Nordic countries and one in The Netherlands. All patients referred for this condition is included, to outline detailed preoperative chara…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Could a rheumatoid arthritis drug calm a rare brain disease?
Disease control CompletedThe primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production
Phase 2 • Sponsor: Adeline Vanderver, MD • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC